Pierre Fabre Medicament and Forest Laboratories to Collaborate on Development and Commercialization of F2695 for Depression
December 22 2008 - 8:00AM
PR Newswire (US)
NEW YORK and PARIS, Dec. 22, 2008 /PRNewswire-FirstCall/ -- Forest
Laboratories, Inc. (NYSE:FRX) and Pierre Fabre Medicament today
announced that they have entered into a definitive collaboration
agreement to develop and commercialize F2695 in the United States
and Canada. F2695 is a proprietary selective norepinephrine and
serotonin reuptake inhibitor that is being developed by Pierre
Fabre for the treatment of depression and other central nervous
system disorders. (Logo:
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) Under the
terms of the agreement, Forest will make an upfront payment to
Pierre Fabre of $75 million and will pay future, undisclosed
milestone payments. In addition, Pierre Fabre will receive royalty
payments based on F2695 sales. Forest will assume responsibility
for the clinical development and commercialization of F2695 in the
United States and Canada, while Pierre Fabre will fund all
preclinical development and drug substance manufacturing activities
worldwide. "We are pleased to expand our relationship with Pierre
Fabre to include this collaboration on the development of F2695 for
the treatment of depression. Pierre Fabre has been an outstanding
partner for Forest since we commenced our alliance in 2004,"
commented Howard Solomon, Chairman and Chief Executive Officer of
Forest. "We are highly encouraged by the strong clinical
antidepressant activity and good tolerability exhibited by F2695 in
the recently completed placebo-controlled, double-blind Phase II
study. We look forward to initiating Phase III studies with F2695
next year. F2695 is the second late-stage product candidate we have
licensed this quarter, underscoring our commitment to further
building our pipeline and bringing novel therapeutics to the
market." "Pierre Fabre is looking forward to working with Forest on
this exciting product opportunity," said Jean-Pierre Garnier, Chief
Executive Officer of Pierre Fabre Medicament. "Forest has an
excellent record of developing and commercializing products for the
treatment of depression and we are happy to extend our existing
partnership to include F2695." In a recently completed European
placebo-controlled, double-blind Phase II study of F2695 in over
550 patients with major depressive disorder, the compound
demonstrated statistically significant improvement compared to
placebo (p
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024